The aim of this tool is to predict the progression-free survival of patients with well-differentiated gastroenteropancreatic neuroendocrine tumors, with metastases, at the onset of first-line therapy with somatostatin analogues (Sandostatin LAR or Lanreotide Autogel) in monotherapy. This tool is intended only for patients with these characteristics; hence, the eligibility criteria will be checked before you can access the calculator. The data come from the Spanish Group of Neuroendocrine Tumors (R-GETNE) registry that represents the clinical practice patterns of the participating centers. Although this model offers an overview, bear in mind that a minority of your patients may have unusual prognostic factors, which could significantly affect the clinical evolution.
Predictions are merely approximate, so decisions should be made at the discretion of the attending physician.